Rheumatoid Arthritis Therapeutics Market Report (2022 to 2030) – Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Amgen Inc., and AbbVie Inc.

Pune, Oct. 17, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global rheumatoid arthritis therapeutics market is expected to clock US$ 2.42 billion by 2030 and to grow at a CAGR of 6.14% during the forecast period. As the high prevalence of arthritis and increasing uptake of biopharmaceuticals is noted. This exclusive information is published by Growth Plus Reports in its report titled “Rheumatoid Arthritis Therapeutics Market – Global Outlook & Forecast 2022-2030”

Excerpts from ‘Competitive Landscape’

Some prominent players operating in the rheumatoid arthritis therapeutics market are

• Johnson & Johnson Services Inc
• F. Hoffman-La Roche Ltd
• Merck & Co., Inc
• Novartis AG Pfizer Inc
• UCB S.A
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc
• Regeneron Pharmaceuticals Inc
• Boehringer Ingelheim GmbH
• AbbVie Inc

Download PDF Brochure of Rheumatoid Arthritis Therapeutics Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/rheumatoid-arthritis-therapeutics-market/7891

Advances in biologics are increasing the growth of the global rheumatoid arthritis therapeutics market. In patients with moderate to severe rheumatoid arthritis, biologics treatments target particular immune response components that are very helpful in easing symptoms, delaying disease onset, and enhancing physical function and other aspects of quality of life. The recently approved biologic pleiotropic cytokine interleukin 6 (IL-6) plays a crucial part in the pathogenesis of rheumatoid arthritis (RA). It is prevalent in the synovial fluid and serum of RA patients, and its amount is correlated with the severity of the disease and the destruction of the joints. In rheumatoid arthritis (RA), IL-17A primarily acts on synoviocytes and osteoblasts to mediate the degradation of cartilage and bone. In vitro research demonstrates that IL-17A causes synoviocyte activation, migration, and invasion that encourage cartilage degeneration.

Market Drivers

The key factors driving the global rheumatoid arthritis market are the increasing aging population, high risk of genetic inheritance, and abrupt lifestyle changes. Obesity is another important risk factor for rheumatoid arthritis. A relationship between obesity and RA is projected to exacerbate the condition. Since biologics treatment can reduce inflammation, developing advanced biologics is also anticipated to drive market growth. Conversely, rising drug prices may be constrained by the global market for rheumatoid arthritis therapeutics.

Excerpts from ‘by Drug Class’

According to the drug class, the global rheumatoid arthritis market is segmented into:

• Biopharmaceuticals
• Pharmaceuticals

The pharmaceuticals segment has dominated the market. The Pharmaceutical segment is further divided into analgesics and non-steroidal anti-inflammatory agents. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely utilized for symptomatic therapy of rheumatic disorders of acute and chronic musculoskeletal pain. The immediate impact of these non-steroidal anti-inflammatory drugs is to reduce acute inflammation, lowering pain, and increase general function. In certain circumstances, studies show that lower dosages of NSAIDs help reduce inflammation in rheumatoid arthritis.

Excerpts from ‘by Route of Administration’

According to the route of administration, the global rheumatoid arthritis therapeutics market is grouped into:

The parenteral segment has a high demand for the treatment of rheumatoid arthritis. The growth of the segment is supported by advantages such as there is no risk of the medication being broken down by the digestive system due to the drug’s rapid absorption and the onset of effect.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/rheumatoid-arthritis-therapeutics-market/7891

Excerpts from ‘By Region’

According to geography, the global rheumatoid arthritis market is segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the world

North America has dominated the market. Factors influencing the growth in this region are the presence of an advanced healthcare system, high prevalence of disease, domicile of key market players in the area, and availability of favorable reimbursement policies. The European market for rheumatoid arthritis is driven by factors such as the growing presence of the geriatric population affected by the disease, the high number of novel drugs introduced in the market, and robust pipeline drugs. The Asia Pacific market for rheumatoid arthritis therapeutics is expected to grow in the projected period due to the perpetually growing patient population and increased awareness about the drugs available for rheumatoid arthritis treatment.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1.    Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints
   3. Opportunities
5. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
   1. Biopharmaceuticals 
      1. Biosimilars
      2. Biologics
   2. Pharmaceuticals 
      1. Analgesics 
      2. NSAIDs (Non-Steroidal Anti-Inflammatory Agents)

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Directly Purchase Premium Copy of Rheumatoid Arthritis Therapeutics Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=0ZUPDOBbBxSQ4DPSAdedoxvwchAjGIyQEc69TEOx&report_id=7891&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.